Clinical trialNCT03292588CompletedPhase 2Interventional

A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment335Asthma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to see if treatment with a medication called Nucala® (mepolizumab), given along with standard asthma care, makes children less likely to have asthma attacks.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel J Jackson, MD
University of Wisconsin, Madison
Study Chair
clinicaltrials.gov ↗
William W Busse, MD
University of Wisconsin, Madison
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Colorado
Aurora, Colorado, United States
Children'S National Medical Center
Washington D.C., District of Columbia, United States
Ann and Robert Lurie Children'S Hospital of Chicago
Chicago, Illinois, United States
Boston Medical Center
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
St. Louis Children'S Hospital
St Louis, Missouri, United States
Columbia University Medical Center
New York, New York, United States
Cincinnati Children'S Hospital
Cincinnati, Ohio, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Mepolizumab →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Nov 2017
Primary completion: 20 Apr 2021
Completion: 20 Apr 2021
Last update posted: 20 Jul 2022
Registered enrollment: 335
Registry id: NCT03292588

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.